

Curriculum Vitae

Personality

Name LEITER-STÖPPKE Ulrike Martina Barbara MD
Professor of Dermatology

Address Center of Dermatooncology, Department of Dermatology
Eberhard-Karls-University of Tuebingen
Liebermeisterstr. 25, 72076 Tuebingen
GERMANY
Phone: 07071-29-84596
Email: ulrike.leiter@med.uni-tuebingen.de

Education and Profession

5/1990 Abitur (German university entrance qualification)
10/1990-5/1997 Medical University of Ulm
5/1997 Medical License and Medical Doctor, University of Ulm
5/1998 PhD Department of Internal Medicine I, University of Ulm: "Expression of the apoptosis genes bcl-2, bcl-xL/S and bax in human pancreatic cancer cell lines and pancreatic carcinomas", magna cum laude
5/1997-10/2001 Resident in Dermatology, University of Ulm
9/2001 Consultant in Dermatology and Venerology
10/2001 until now of Tuebingen, Center of Dermato-Oncology, Department of Dermatology, University
04/2010 Qualification "palliative medicine" and "medical tumor therapy"
12/2010 Venia legendi (Habilitation), University of Tuebingen
02/2018 Professor of Dermatology

Awards

Grants

Membership

Reviewing Board

German Skin Cancer Award (2016)
Research project: Treatment Patterns and Outcomes for Cutaneous Squamous Cell Carcinoma in Germany (2018)
European Society of Pigment Cell Research
German Dermatological Society
German Cancer Society
American Society of Clinical Oncology
European Society of Dermatooncology
Skin care in Organ Transplant Patients (Europe)
European Journal of Cancer, British Journal of Dermatology, Journal of the German Society of Dermatology, Journal of the European Association of Dermatology and Venerology, Melanoma Research, Discovery Medicine, Future Oncology, Expert Reviews of Dermatology, Lancet Oncology
Reviewer for the German Research Foundation



5 important publications:

1. **Leiter U**, Loquai C, Reinhardt L, Rafei-Shamsabadi D, Gutzmer R, Kaehler K, Heinzerling L, Hassel JC, Glutsch V, Sirokay J, Schlecht N, Rübber A, Gambichler T, Schatton K, Pfoehler C, Franklin C, Terheyden P, Haferkamp S, Mohr P, Bischof L, Livingstone E, Zimmer L, Weichenthal M, Schadendorf D, Meiwes A, Keim U, Garbe C, Becker JC, Ugurel S. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. *J Immunother Cancer*. 2020; 8. IF 10.52

2. **Leiter U**, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, Sunderkotter C, Kaatz M, Schatton K, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Verver D, Martus P, Garbe C. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2019; 37: 3000-08. IF 36.4

3. Hillen U, **Leiter U**, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, Ulrich J, Machens HG, Weishaupt C, Hauschild A, Mohr P, Pföhler C, Maurer J, Wolff P, Windemuth-Kieselbach C, Schadendorf D, Livingstone E; Dermatologic Cooperative Oncology Group. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. *Eur J Cancer*. 2018, IF=7.19

4. **Leiter U**, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, Garbe C. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. *J Invest Dermatol*. 2017 Sep;137(9):1860-1867. IF= 6.45

5. **Leiter U**, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte KW, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Martus P, Garbe C; German Dermatologic Cooperative Oncology Group (DeCOG). Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2016 Jun;17(6):757-67. doi: 10.1016/S1470-2045(16)00141-8. IF. 36.4

Third party funding

Project title	Source of funds	Duration (MM/YY – MM/YY)	Amount of financial support
Treatment Patterns and Outcomes for Cutaneous Squamous Cell Carcinoma (cSCC) in Germany	MSD	12/2018-06/2019	82.000 €